

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/614,076	07/03/2003	Leigh H. English	MECO:218-1 11792.0218.DVU	8919
45607	7590 04/04/2006		EXAM	INER
HOWREY	LLP		KUBELIK,	ANNE R
C/O IP DOC	KETING DEPARTMENT			
2941 FAIRVIEW PARK DRIVE SUITE 200			ART UNIT	PAPER NÚMBER
FALLS CHURCH, VA 22042			1638	-

DATE MAILED: 04/04/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
•	10/614,076	ENGLISH ET AL.			
Office Action Summary	Examiner	Art Unit			
	Anne R. Kubelik	1638			
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period v  - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).			
Status					
Responsive to communication(s) filed on 19 December 2a) ☐ This action is <b>FINAL</b> . 2b) ☐ This 3) ☐ Since this application is in condition for alloware closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro	esecution as to the merits is			
Disposition of Claims					
4) ☐ Claim(s) 38-49 is/are pending in the application 4a) Of the above claim(s) is/are withdraw 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 38-49 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or Application Papers  9) ☐ The specification is objected to by the Examiner 10) ☐ The drawing(s) filed on is/are: a) ☐ access Applicant may not request that any objection to the ore Replacement drawing sheet(s) including the correction in the oregin of the correction of the oregin of the origin of	vn from consideration.  r election requirement.  r.  epted or b) □ objected to by the Edrawing(s) be held in abeyance. See ion is required if the drawing(s) is obj	e 37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some * c) None of:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.					
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  Paper No(s)/Mail Date	4) Interview Summary ( Paper No(s)/Mail Da 5) Notice of Informal Pa 6) Other:				

Application/Control Number: 10/614,076 Page 2

Art Unit: 1638

## **DETAILED ACTION**

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 27 February 2006 has been entered.

- 2. Claims 38-49 are pending.
- 3. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

## Claim Rejections - 35 USC § 112

4. Claims 38-49 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter that was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. The rejection is modified from the rejection set forth in the Office action mailed 23 September 2005, as applied to claims 38-46, due to Applicant's amendment of the claims. Applicant's arguments filed 19 December 2005 have been fully considered but they are not persuasive.

Neither the instant specification nor the originally filed claims appear to provide support for the phrase "one or more point mutations ... Gln348 to arginine" in claim 38, lines 5-11, claim 39, lines 14-18 and claim 46, lines 2-5, the phrase "one or more point mutations ... Lys189 to Gly" in claim 44, lines 6-8, and the phrase "one or more amino acids is selected ... lysine or

Application/Control Number: 10/614,076

Art Unit: 1638

valine" in claim 40, lines 24-7. Thus, such phrases constitute NEW MATTER. In response to this rejection, Applicant is required to point to support for the phrase or to cancel the new matter.

Applicant urges that support for Arg162 to His was found in the amendment to Table 2 filed 3/1/05 (response pg 6).

There was no amendment filed on that date; however, the amendment filed 6/30/05 does provide support as the amendment corrects an error. Amendments before final are entered as a matter of course. This portion of the rejection is withdrawn.

Applicant points to places in the specification that recite "one or more mutations" (response pg 6-7).

This is not found persuasive, as there is no support for the particular combinations of mutations recited in the claims, either before the current amendment or after, nor is there any support for mixing and matching the mutations in Table 2.

Applicant urges that the mutations "Leu158 to Arg ... Lys189 to Gly" are all in or near the  $\alpha$  helix 4 region, and there are examples in the specification that have at least one of these (response pg 7-8).

This is not found persuasive. There is no support in the specification for the particular combination of one of those mutations in combination with any or all of the further mutations. Each of the cited examples only provide support for the particular combination of substitutions made in those variants.

Applicant urges that support for mutations of Asp165 to Gly and one or more of the mutations at amino acids 311, 33 and 317 is found in the specification and Table 2 (response pg 8).

This is not found persuasive, as there is no support for the particular mutations recited in the claims, nor is there any support in the specification for mixing and matching the mutations in Table 2. Each of 11082, 11098, 11081 and 11084 only provide support for the particular combination of substitutions made in those variants, and some of these variants have mutations other than those recited in the claim.

Applicant urges that the phrase "one or more amino acids is selected ... lysine or valine" in claim 40, lines 24-7 is supported by pg 31, lines 8-12 and various variants (response pg 9).

This is not found persuasive because there is no support in the specification for mixing and matching the particular mutations and substitutions. None of the recited variants, for example, has Asn313 to valine or Glu317 to alanine or to valine with any substitution in Ser311.

5. Claims 47-49 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter that Applicant regards as the invention. Dependent claims are included in all rejections.

Claim 47 lacks antecedent basis for the limitation "said one or more amino acid replacement" in lines 1-2.

## Conclusion

- 6. No claim is allowed.
- 7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Anne R. Kubelik, whose telephone number is (571) 272-0801. The examiner can normally be reached Monday through Friday, 8:30 am 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anne Marie Grunberg, can be reached at (571) 272-0975.

The central fax number for official correspondence is (571) 273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Art Unit: 1638

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

Anne Kubelik, Ph.D. March 29, 2006

ANNE KUBELIK, PH.D. PRIMARY EXAMINER